Fintel reports that on December 2, 2024, Citigroup initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Buy ...

Our findings show that since 2016, tobacco shares have substantially underperformed the market, cigarette consumption has ...

In my previous Rivian article, I urged investors not to fall in love with the stock, even as it has plunged deep into ... As ...

The U.S. Postal Service today announced many of the stamps it will release in 2025. "This early glimpse into our 2025 stamp ...

This is why VYGR’s TRACER platform can be a game changer for therapies without an adequate delivery mechanism before VYGR ...

Researchers and scientists are turning to artificial intelligence (AI) as a potentially powerful tool in the fight to slow ...

Organisations such as Tobacco Free Portfolios urge institutions not to invest in or provide financial services to tobacco ...

RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones ... of the Rejuva program and increased personnel-related expenses, including stock-based compensation.

Therefore, taking stock of the milestones and progress achieved in countries ... The UK’s Alan Turing Institute and Canada’s Vector Institute are global leaders in AI research, and both countries have ...

Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript November 4, 2024 Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank ...

AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today ...